Harnessing biomarker and phenotypic diversity among adolescents and women with endometriosis to advance personalized medicine for diagnosis and pain remediation
利用患有子宫内膜异位症的青少年和女性的生物标志物和表型多样性来推进诊断和疼痛治疗的个性化医疗
基本信息
- 批准号:9921458
- 负责人:
- 金额:$ 21.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-01 至 2022-04-30
- 项目状态:已结题
- 来源:
- 关键词:8-hydroxy-2&apos-deoxyguanosineAccountingAddressAdolescenceAdolescentAdultAdvanced DevelopmentAffectAftercareAgeAlgorithmsAmericanBiologicalBiological MarkersBostonBrain-Derived Neurotrophic FactorCharacteristicsClinicalCommunitiesComplementary and alternative medicineDataDevelopmentDiagnosisDiagnosticDiagnostic testsDiseaseDisease ProgressionEnrollmentEpidemiologyEtiologyExcisionFaceFailureFemaleFertilityFoundationsGeneticHealthHealth Care CostsHeterogeneityHospitalsImmune responseInfertilityInflammationInflammatoryInterleukin-10Interleukin-6InternationalLaparoscopic Surgical ProceduresLeadLesionLife StyleLongitudinal cohort studyMeasuresMedicalMedical HistoryModalityMonitorMorbidity - disease rateOncologyOperative Surgical ProceduresOxidative StressPainParticipantPatientsPelvic PainPersonal SatisfactionPharmaceutical PreparationsPharmacologic SubstancePhenotypeProtocols documentationQuality of lifeRefractoryReportingReproductive HistoryReproductive MedicineResearchResistanceRiskSamplingSelection for TreatmentsSeveritiesSiteSocietiesSpecificityStagingSymptomsTNF geneTestingTimeVisualizationWomanWomen&aposs Healthaccurate diagnosisagedbasebiobankcase controlcentral paincentral sensitizationchronic painchronic pelvic paincohortdisorder subtypeeffective therapyendometriosisexperiencefunctional statushealth economicshigh rewardhigh riskindexinginnovationmultidisciplinarynoninvasive diagnosisoptimal treatmentsoutcome forecastpain symptompersonalized medicinephenomephenotypic dataprecision medicineprediction algorithmpsychological symptomremediationreproductivesample collectionscreeningstandard caresuccesstooltraittreatment responseyoung woman
项目摘要
Project Summary/Abstract
Endometriosis is a common disease among reproductive aged adolescents and women and can lead to
debilitating pelvic pain, infertility, reduced quality of life and significant health care costs. Currently laparoscopic
surgery is the only means for providing a definitive diagnosis of endometriosis. The average delay to diagnosis
from symptom onset is 7 years, potentially leading to unchecked endometriotic lesion progression and
increased risk and severity of morbidity later in adulthood. While numerous studies have investigated non-
invasive screening tests for diagnosing endometriosis, none have proven to have sufficient specificity and/or
sensitivity to replace laparoscopic surgery. Further, once an adolescent or woman has been diagnosed with
endometriosis she often faces a struggle to find the most effective treatment modality to relieve endometriosis-
related symptoms. While the revised American Society for Reproductive Medicine endometriosis staging and
the Endometriosis Fertility Index have been used to predict prognosis after endometriosis diagnosis; neither is
specific to predicting if adolescents and women will experience pain remediation. Additionally, a subset of
endometriosis patients will develop central sensitization leading to treatment refractory chronic pelvic pain. The
lack of discovery for a non-invasive screening test for endometriosis diagnosis and for monitoring disease
progression may be due to considering endometriosis as a single entity and not including the full heterogeneity
in symptom profiles and patient characteristics to assess diagnosis and pain remediation after treatment. Our
proposal fills this scientific gap by (1) investigating a non-invasive diagnostic for endometriosis combining
patient symptoms and characteristics with inflammatory, oxidative stress and central sensitization biomarkers;
(2) assessing changes in inflammatory, oxidative stress and central sensitization biomarkers before and after
surgery; and (3) determining the optimal set of patient symptoms and characteristics in addition to
inflammatory, oxidative stress and central sensitization biomarkers to advance personalized treatment
selection. We will assess inflammatory and oxidative stress biomarkers as an aberrant immune response and
increased oxidative stress have been implicated in endometriosis etiology and progression. Collectively, these
aims have the potential to advance our understanding of phenotypic diversity among adolescents and women
with endometriosis; diversity that will be the foundation for successful personalized, precision medicine to
shorten diagnostic delay and maximize pain remediation. Success will reduce health care costs and increase
long-term health and quality of life for adolescents and women with endometriosis.
项目概要/摘要
子宫内膜异位症是育龄青少年和妇女的常见疾病,可导致
使人衰弱的盆腔疼痛、不孕、生活质量下降和高昂的医疗费用。目前腹腔镜
手术是明确诊断子宫内膜异位症的唯一方法。平均诊断延迟
从症状出现起 7 年,可能导致子宫内膜异位病变进展不受控制
成年后期发病的风险和严重程度增加。虽然大量研究调查了非
用于诊断子宫内膜异位症的侵入性筛查测试,尚未证明具有足够的特异性和/或
敏感性取代腹腔镜手术。此外,一旦青少年或女性被诊断出患有
子宫内膜异位症 她经常面临寻找最有效的治疗方式来缓解子宫内膜异位症的斗争 -
相关症状。虽然修订后的美国生殖医学会子宫内膜异位症分期和
子宫内膜异位症生育指数已用于预测子宫内膜异位症诊断后的预后;也不是
具体用于预测青少年和女性是否会经历疼痛治疗。此外,一个子集
子宫内膜异位症患者会产生中枢敏化,导致治疗难治性慢性盆腔疼痛。这
缺乏用于子宫内膜异位症诊断和疾病监测的非侵入性筛查试验的发现
进展可能是由于将子宫内膜异位症视为一个单一实体而不包括完整的异质性
症状概况和患者特征,以评估治疗后的诊断和疼痛缓解。我们的
该提案通过以下方式填补了这一科学空白:(1)研究子宫内膜异位症的非侵入性诊断,结合
患者症状和炎症、氧化应激和中枢致敏生物标志物的特征;
(2)评估治疗前后炎症、氧化应激和中枢致敏生物标志物的变化
外科手术; (3) 确定一组最佳的患者症状和特征
炎症、氧化应激和中枢敏化生物标志物以推进个性化治疗
选择。我们将评估炎症和氧化应激生物标志物作为异常的免疫反应,
氧化应激增加与子宫内膜异位症的病因和进展有关。总的来说,这些
目标有可能增进我们对青少年和女性表型多样性的理解
患有子宫内膜异位症;多样性将成为成功的个性化精准医疗的基础
缩短诊断延迟并最大限度地缓解疼痛。成功将降低医疗保健成本并增加
患有子宫内膜异位症的青少年和妇女的长期健康和生活质量。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Cohort profile: The Endometriosis pain QUality aftEr Surgical Treatment (EndoQUEST) Study.
- DOI:10.1371/journal.pone.0269858
- 发表时间:2022
- 期刊:
- 影响因子:3.7
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STACEY ANN MISSMER其他文献
STACEY ANN MISSMER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STACEY ANN MISSMER', 18)}}的其他基金
Endogenous Hormones and Risk of Endometriosis
内源性激素和子宫内膜异位症的风险
- 批准号:
7248571 - 财政年份:2006
- 资助金额:
$ 21.4万 - 项目类别:
Endogenous Hormones and Risk of Endometriosis
内源性激素和子宫内膜异位症的风险
- 批准号:
7022519 - 财政年份:2006
- 资助金额:
$ 21.4万 - 项目类别:
相似海外基金
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study
GBM 中的 6-硫代-2-脱氧鸟苷:药效学评估、先前护理标准的影响和人类 0 期研究
- 批准号:
10305569 - 财政年份:2021
- 资助金额:
$ 21.4万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Evaluation of Pharmaco-dynamics, Effects of Prior Standard of Care and A Human Phase 0 Study
GBM 中的 6-硫代-2-脱氧鸟苷:药效学评估、先前护理标准的影响和人类 0 期研究
- 批准号:
10488244 - 财政年份:2021
- 资助金额:
$ 21.4万 - 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
- 批准号:
10305565 - 财政年份:2021
- 资助金额:
$ 21.4万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
- 批准号:
10488242 - 财政年份:2021
- 资助金额:
$ 21.4万 - 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
- 批准号:
10488237 - 财政年份:2021
- 资助金额:
$ 21.4万 - 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
- 批准号:
10305568 - 财政年份:2021
- 资助金额:
$ 21.4万 - 项目类别:
RUI: Chemical Investigations into the Bioactivity of the DNA Lesion 8-Oxo-2'-deoxyguanosine
RUI:DNA 损伤 8-Oxo-2-脱氧鸟苷生物活性的化学研究
- 批准号:
1903855 - 财政年份:2019
- 资助金额:
$ 21.4万 - 项目类别:
Standard Grant
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
- 批准号:
311600-2013 - 财政年份:2017
- 资助金额:
$ 21.4万 - 项目类别:
Discovery Grants Program - Individual
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
- 批准号:
311600-2013 - 财政年份:2015
- 资助金额:
$ 21.4万 - 项目类别:
Discovery Grants Program - Individual
Toxicity and Biosensing Properties of C8-Aryl-Deoxyguanosine Adducts
C8-芳基-脱氧鸟苷加合物的毒性和生物传感特性
- 批准号:
311600-2013 - 财政年份:2014
- 资助金额:
$ 21.4万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




